anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a traditional Chinese medicine paste for treating various rheumatisms (commonly called arthritis), which is finally developed successfully by more than 7 years through experiments of which the number is more than 2000 times. The emulsified paste and the chemical paste of the traditional Chinese medicine paste for treating various rheumatisms are same, and the traditional Chinese medicine paste for treating various rheumatisms has strong skin penetrability, high absorptivity, a strong medicine effect and high capacity. As the technological superiority is perfect, the traditional Chinese medicine paste for treating various rheumatisms is capable of treating all surgical rheumatisms, vascular stasis and has the effects of pain stopping, inflammation diminishing, detumescence and quick results, and the cure rate can reach 100 percent, wherein the rheumatisms, scapulohumeral periarthritis, vascular sclerosis and stasis and the like are healed for 5-15 days of course of treatment, and cervical vertebra and lumbar vertebra are healed for about 20 days. The traditional Chinese medicine paste for treating various rheumatisms has a good effect on treating osteoproliferation and herniated disk, has an excellent and rapid effect on the pain stopping, the inflammation diminishing and the detumescence in a bone fracture surgical department and is capable of filling the gap of an external art. The blank of the world is filled by the traditional Chinese medicine paste prepared by the art of the invention. The traditional Chinese medicine paste for treating various rheumatisms has extremely strong applicability and an infinitely superior popularization value. The curative effect and the cure rate of the traditional Chinese medicine paste for treating various rheumatisms far exceed that of products of all domestic and international prior arts, including brand name products and the products with national secrecy prescriptions.
A drug for improving brain functions, comprising a specified 2-phenyl-3-oxo-2H-1,4-benzothiazine derivative. It is effective in treating various diseases accompanied by lowering in brain functions, such as those caused by cerebral ischemia, e.g. cerebral infarction or transient cerebral ischemia, those caused as the sequela of brain edema, cerebral hemorrhage, etc., those caused by injuries, e.g. contusion, or central nervous system degeneration and regressive diseases, e.g. dementia, psychosis. neurosis, or Alzheimer disease.
Over 30 million people have chronic kidney disease (CKD) and nearly 100,000 people are awaiting renal transplant for end stage renal disease (ESRD). Renal transplant, when compared to dialysis, improves quality of life, is more cost-effective, and reduces the risk of cardiovascular disease. However, many patients who are eligible for transplant become deconditioned while waiting for organ transplantation, and may be taken off the transplant waitlist for concerns the patient will not be able to tolerate surgery. Moreover, poor physical functioning prior to transplant was associated with a 2.5-fold increased risk for delayed graft function and 2.30 fold higher risk of patient death after renal transplant. Our team has also shown that functional limitations, such as slower gait speed and poorer grip strength, were associated with not being waitlisted for transplant and decreased survival in all transplant candidates undergoing evaluation. Functional limitation may reduce the individuals' overall level of physical activity, which can increase further disability. While physical activity (PA) interventions have been shown to be effective in reducing morbidity and mortality in other chronic diseases, no study has tested the efficacy of a PA intervention in patients awaiting renal transplant. Family caregivers are integral in the care of renal transplant candidates. Decades of research has shown that family caregivers are at increased risk for cardiovascular disease (CVD) and mortality when compared to non-caregivers. Investigators propose to include the family caregivers in the PA intervention to improve patient adherence to the intervention while reducing the caregivers' risk for CVD. The proposed study addresses several of the recommendations from consensus meeting on exercise in solid organ transplant which included testing a PA intervention in a large-scale trial with both standard and surrogate markers, using a novel technology-assisted delivery of the intervention, and focusing on mechanisms linking PA with health outcomes.
Pembrolizumab 200 mg, IV infusion on Day 1 of each 3 week cycle. After 3 cycles patient will be evaluated. In case of disease control (SD, PR, CR) the patient will continue to receive pembrolizumab. In case of progression the patient will receive also Cetuximab (250 mg/m2 after loading dose of 400mg/m2 IV infusion every week.
Randomisation 2 will only be relevant if participants are advised by their clinical team to have a biopsy based on their MRI and other clinical factors. Participants advised to have a biopsy will undergo an image fusion targeted biopsy.
PURPOSE: A composition containing Sequoia callus extract is provided to promote regeneration of adipose-derived stem cells and to recover damaged subcutaneous fat. CONSTITUTION: A composition for enhancing the stemness of adipose-derived stem cells(hADSCs) contains Sequoia callus extract as an active ingredient. The composition enhances CD29 and CD44 expression level. A composition for enhancing skin cell proliferation contains the extract as an active ingredient. The skin cell is transit-amplifying cells(TA cells). The composition contains 0.0001-10 wt% of the extract. A skin care method comprises a step of treating the composition on the skin.
Accumulating evidence highlights the involvement of astrocytes in Alzheimer's disease (AD) progression. We have previously demonstrated that human iPSC-derived astrocytes ingest and modify synthetic tau fibrils in a way that enhances their seeding efficiency. However, synthetic tau fibrils differ significantly from in vivo formed fibrils. To mimic the situation in the brain, we here analyzed astrocytes' processing of human brain-derived tau fibrils and its consequences for cellular physiology. Tau fibrils were extracted from both AD and control brains, aiming to examine any potential differences in astrocyte response depending on the origin of fibrils. Our results show that human astrocytes internalize, but fail to degrade, both AD and control tau fibrils. Instead, pathogenic, seeding capable tau proteoforms are spread to surrounding cells via tunneling nanotubes and exocytosis. Notably, accumulation of AD tau fibrils induces a stronger reactive state in astrocytes, compared to control fibrils, evident by the augmented expression of vimentin and GFAP, as well as by an increased secretion of the pro-inflammatory cytokines IL-8 and MCP-1. Moreover, conditioned media from astrocytes with AD tau fibril deposits induce synapse and metabolic impairment in human iPSC-derived neurons. Taken together, our data suggest that the accumulation of brain-derived AD tau fibrils induces a more robust inflammatory and neurotoxic phenotype in human astrocytes, accentuating the nature of tau fibrils as an important contributing factor to inflammation and neurodegeneration in AD.
AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
OBJECTIVE: In this study, we describe our experience utilising Advisor™ High Density (HD) Grid mapping catheter in transcatheter ablation of intraatrial re-entrant and focal atrial tachycardias with or without CHD.
METHODS: Forty-five consecutive patients with intraatrial re-entrant and focal atrial tachycardia who underwent a transcatheter ablation procedure by using Advisor™ HD Grid mapping catheter and high-density mapping system in our hospital from January 2017 to January 2023 were included into the study.
RESULTS: The mean age of the patients was 14.2 ± 7.3 years (6-32 years), and the mean weight was 48.3 ± 16.2 kg (22-83 kg). Of the total 45 patients, 21 were intraatrial re-entrant tachycardia and 25 were focal atrial tachycardia. Of the 21 re-entrant circuits, 15 were classified as cavotricuspid isthmus-dependent and 5 were non-cavotricuspid isthmus-dependent. In one patient, two re-entrant circuits were identified. A transbaffle ablation was successfully performed from the left atrium in one patient. Of the 25 focal atrial tachycardia, 19 were from right atrium and 6 were from left atrium. A cryoablation was performed in only one patient and radiofrequency ablation in others. The mean procedure time was 180 ± 64 minutes. The mean follow-up period was 69.3 ± 35.3 months. Acute success was 95.5%. Recurrence was noted in two patients (4.4%).
CONCLUSION: Advisor™ HD Grid mapping catheter was found to be safe and achieved an acceptable success in transcatheter ablation of patients with intraatrial re-entrant tachycardia and focal atrial tachycardias.
Disclosed herein are system, method, and computer program product embodiments for data anonymization in an in-memory database. An embodiment operates by receiving an indication to perform data anonymization based on one or more quasi attributes of a data set. The data set is sorted based on the one or more quasi attributes. The sorted data set is grouped into a first plurality of groups. A particular group that does not include enough records to satisfy an anonymization threshold is identified from amongst the first plurality of groups. The particular group is combined with another group of the first plurality of groups.
PURPOSE:To obtain the titled composition having mitigated side effects, improved absorbability of drug component and improved light stability, by suspending natural albumin in an aqueous solution, adding a drug exhibiting protein-bonding action to the suspension, stirring the mixture at a high speed and removing the solvent. CONSTITUTION:A natural albumin (preferably ovalbumin) is suspended in an aqueous solution (preferably water) to obtain a suspension having a concentration of 2-25wt.%. A drug exhibiting protein-bonding property (e.g. nalidixic acid) is dissolved in an organic solvent having a boiling point of <=100 deg.C (e.g. acetone), added to the suspension and agitated at 4-30 deg.C at a high speed (5,000-40,000rpm) for 1-30hr to obtain a homogeneous layer. The organic solvent is removed from the layer by distillation under reduced pressure and the residue is dried to obtain a pharmaceutical composition composed of 1-200pts. of the drug component and 100pts. of natural albumin. The composition can reduce the injury on especially digestive system and increase the content of the drug component.
Acute gastroenteritis is a major cause of pediatric morbidity and mortality accounting for 15 % of all childhood death worldwide, and is a major public health burden, especially in developing countries. A recent Cochrane review of 33 randomized or quasi-randomized trials reported a modest reduction in the duration of diarrhea in children younger than 5 years who were on reduced or lactose-free diet. Those trials however were conducted on inpatients in high or middle-income countries. None were from developing countries where diarrheal diseases are severer and result in higher morbidities and mortalities. This study aims at investigating the effect of lactose-free milk on the duration and severity of diarrhea in infants from a developing country, who present with acute gastroenteritis to the Emergency Department (ED) or pediatric clinics. The findings from this study will help provide evidence-based dietary recommendations for infants with acute diarrhea in developing countries who are treated in the ambulatory setting.
<P>PROBLEM TO BE SOLVED: To provide an antimicrobial agent comprising one or two or more extracts selected from Apocynum venetum L., Vaccinum myrtillus L. and Acanthopanax senticosus (Rupr. Et Maxim.) Harms.  <P>SOLUTION: The antimicrobial agent comprises the one or two or more extracts selected from the Apocynum venetum L., Vaccinum myrtillus L. and Acanthopanax senticosus (Rupr. Et Maxim.) Harms. The extracts from the Apocynum venetum L., Vaccinum myrtillus L. and Acanthopanax senticosus (Rupr. Et Maxim.) Harms. exhibit a particularly excellent antimicrobial activity against Streptococcus mutans which is a causative bacterium of dental caries (carious teeth) and Helicobacter pylori, etc., which are causative bacteria of gastric ulcer, duodenal ulcer and gastritis and are used for foods, medicines and cosmetics.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Same as group 3, the only difference is that an expert will actively participate in the discussion by commenting on each video on GEN, enhancing students' educational experience. Although anonymous, students will be able to identify the expert as the name "expert" will be used. The expert will answer any question and comment on the discussion in order to guide the students.
Patients randomized to this arm will receive a single-bolus intravenous injection of dexamethasone 20 mg at day 1 (as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization. Patients randomized to this arm will also receive standard-of-care therapy for acute heart failure.
Usual care subjects will not receive a blood pressure cuff or bidirectional text messaging. They will be asked to take their medication and monitor BP as usual with no additional contact from study staff until the 4 month study follow-up.
The present invention discloses a novel preparation method for making aucklandia root capsules of six ingredients and derivation preparation thereof. The present invention is characterized in that volatile oil in aucklandia root, cardamom and long pepper of a novel capsule component is extracted to be wrapped by cyclodextrin to be spare; after the oil is extracted, sinter and rhododendron molle are prepared into alcohol extraction grease to be spare/ after the oil is extracted, the sinter, the rhododendron molle, gardenia and pomegranate are prepared into water extraction grease to be spared/ the gardenia and the pomegranate are prepared into the water extraction grease to be spared. Then, spare materials are converted according to national pharmacopoeia prescription requirements, batch charging is added in auxiliary materials to be uniformly mixed to be encapsulated/ uniformly mixed to prepare granules to be encapsulated/ uniformly mixed to prepare micro pills to be encapsulated to finish the whole preparation. Or before capsules are filled, the materials are pressed to be prepared into tablets or formed into granules. The medicine carries out technology innovation on the foundation of the existing dispersant and capsule, the machine is mainly characterized in that the dosage is reduced greatly, the quality control standard is enhanced, and the volatile ingredient reservation and the stabilization are improved greatly. The medicine has the advantages of portability, convenient use, high absorption, safety, stabilization and effectiveness, and the medicine is welcomed by clinics.
BACKGROUND: Fusarium head blight (FHB), a devastating disease of wheat production, is predominantly elicited by Fusarium graminearum (Fg). The tetraploid Thinopyrum elongatum is a tertiary gene resource of common wheat that possesses high affinity and displays high resistance traits against multiple biotic and abiotic stress. We aim to employ and utilize the novel FHB resistance resources from the wild germplasm of common wheat for breeding.
RESULTS: Durum wheat-tetraploid Th. elongatum amphiploid 8801 was hybridized with common wheat cultivars SM482 and SM51, and the F5 generation was generated. We conducted cytogenetically in situ hybridization (ISH) technologies to select and confirm a genetically stable 7E(7D) substitution line K17-1069-5, which showed FHB expansion resistance in both field and greenhouse infection experiments and displayed no significant disadvantage in agronomic traits compared to their common wheat parents in the field. The F2 segregation populations (K17-1069-5 × SM830) showed that the 7E chromosome conferred dominant FHB resistance with dosage effect. We developed 19 SSR molecular markers specific to chromosome 7E, which could be conducted for genetic mapping and large breeding populations marker-assisted selection (MAS) during selection procedures in the future. We isolated a novel Fhb7 allele from the tetraploid Th. elongatum chromosome 7E (Chr7E) using homology-based cloning, which was designated as TTE7E-Fhb7.
CONCLUSIONS: In summary, our study developed a novel wheat-tetraploid Thinopyrum elongatum 7E(7D) K17-1069-5 substitution line which contains stable FHB resistance.
Heterotopic ossification (HO) is a pathological condition characterized by the formation of bone within soft tissues. The development of HO is a result of abnormal activation of the bone formation programs, where multiple signalling pathways, including Wnt/β-catenin, BMP and hedgehog signalling, are involved. The Wnt/β-catenin signalling pathway, a conserved pathway essential for various fundamental activities, has been found to play a significant role in pathological bone formation processes. It regulates angiogenesis, chondrocyte hypertrophy and osteoblast differentiation during the development of HO. More importantly, the crosstalk between Wnt signalling and other factors including BMP, Hedgehog signalling, YAP may contribute in a HO-favourable manner. Moreover, several miRNAs may also be involved in HO formation via the regulation of Wnt signalling. This review aims to summarize the role of Wnt/β-catenin signalling in the pathogenesis of HO, its interactions with related molecules, and potential preventive and therapeutic measures targeting Wnt/β-catenin signalling.
B-DIT is based on the same treatment principles as face-to-face Dynamic Interpersonal Therapy (DIT) and has the same structure of treatment consisting of three phases: (a) an exploration and engagement phase, (b) a middle or working through phase, and (c) an ending phase. B-DIT consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
The group-based exercise (GBE) programme will be delivered by a physiotherapist. The GBE comprises three sessions per week of group-based exercise in a local community centre, for 8 weeks.
Hypertrophic scars (HS) still remain an urgent challenge in the medical community. Traditional Chinese medicine (TCM) has unique advantages in the treatment of HS. However, due to the natural barrier of the skin, it is difficult for the natural active components of TCM to more effectively penetrate the skin and exert therapeutic effects. Therefore, the development of an efficient drug delivery system to facilitate enhanced transdermal absorption of TCM becomes imperative for its clinical application. In this study, we designed a compound Salvia miltiorrhiza-Blumea balsamifera nanoemulsion gel (CSB-NEG) and investigated its therapeutic effects on rabbit HS models. The prescription of CSB-NEG was optimized by single-factor, pseudoternary phase diagram, and central composite design experiments. The results showed that the average particle size and PDI of the optimized CSB-NE were 46.0 ± 0.2 nm and 0.222 ± 0.004, respectively, and the encapsulation efficiency of total phenolic acid was 93.37 ± 2.56%. CSB-NEG demonstrated excellent stability and skin permeation in vitro and displayed a significantly enhanced ability to inhibit scar formation compared to the CSB physical mixture in vivo. After 3 weeks of CSB-NEG treatment, the scar appeared to be flat, pink, and flexible. Furthermore, this treatment also resulted in a decrease in the levels of the collagen I/III ratio and TGF-β1 and Smad2 proteins while simultaneously promoting the growth and remodeling of microvessels. These findings suggest that CSB-NEG has the potential to effectively address the barrier properties of the skin and provide therapeutic benefits for HS, offering a new perspective for the prevention and treatment of HS.
The invention creates the name: the technical field of Gugong cicada chrysanthemum rhinitis pills: the invention content of the traditional Chinese medicine is as follows: the invention relates to a Chinese medicinal prescription for treating acute and chronic rhinitis and nasosinusitis. Is prepared from 23 Chinese-medicinal materials. Has the functions of dispelling wind, clearing heat, resisting allergy, diminishing inflammation, ventilating lung and relieving stuffy nose. Can be used for treating sneeze, clear nasal discharge, nasal obstruction, smellless odor, headache, nasal pain, even mouth opening at night, and inability to lie flat. Through statistics of 90 cases of return visits in recent three years, the effective rate of the medicine is about 90% after the medicine is taken for one week. The obvious effect of taking the medicine for two weeks or more, and the effect of curing and relieving the relapse of the disease in the next season by 70 percent. Wherein the effect of children is better. For most patients, no other side effects were seen except for a few stomach complaints.
Patients will receive 2 cycles of gemcitabine and abraxane prior to the start of chemoradiation. Chemoradiation will commence 2 week after the completion of second cycle of gemcitabine/abraxane. Patients will receive an additional 2 cycles of gemcitabine and abraxane to start 2-4 weeks after the completion of chemoradiation. After the last two cycles of chemotherapy, if well tolerated with continued tumor response additional cycles of chemotherapy may be given.
The invention relates to a protein SUS2, a gene SUS2, a recombinant expression vector, a transformant and pharmaceutical application thereof, belonging to the field of biological materials. The amino acid sequence of the protein SUS2 is shown as SEQ ID NO. 1. The recombinant protein provided by the invention has good biocompatibility, rich amino acid residues are easy to perform later-stage functionalization, has own specific three-dimensional conformation and function, can be used as a drug carrier, and can realize slow drug release. And the method can be used for rapid mass production, is environment-friendly and has easily controlled quality. The recombinant protein provided by the invention is used as a drug slow-release carrier material, can regulate the drug release speed, has good biocompatibility and biodegradability, and has no toxic or side effect on human bodies.